ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
0 hedge funds and large institutions have $0 invested in ESSA Pharma in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 32 closing their positions.
47.61% less ownership
Funds ownership: 47.61% → 0% (-48%)
100% less funds holding
Funds holding: 32 → 0 (-32)
100% less capital invested
Capital invested by funds: $4.3M → $0 (-$4.3M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 32
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.23M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$833K |
| 3 |
Morgan Stanley
New York
|
-$364K |
| 4 |
P
Pfizer
New York
|
-$320K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$113K |
EPIX Hedge Fund Activity: Q4 2025 in Review
0 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2025, worth a combined $0 — down 100% from $4.3M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of EPIX and 0 opened new positions — a net loss of 32 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BVF Inc, exiting entirely with an estimated $2.23M sold.
- 0 institutional investors held ESSA Pharma (EPIX) as of Q4 2025, down from 32 in Q3 2025.
- Funds reported $0 of ESSA Pharma stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new ESSA Pharma positions in Q4 2025 and 32 closed out, a net change of -32 holders.
- The largest ESSA Pharma seller in Q4 2025 was BVF Inc, an estimated $2.23M sold.
Based on aggregated 13F filings for Q4 2025.